Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end

DELCATH SYSTEMS, INC.

2024-Q1 EPS reported -$0.45 revenue$3,139,000

Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.
Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.
Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.
Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.
SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.

Period: the first quarter ended March 31, 2024
Revenue: $3.1 million
Result: reported results

Exact text from the filing

Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-023065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.